Unique Topical Products for the Relief of Skin Conditions Southeast Virginia Technology Partnership Forum June 15, 2010
43% of al reported skin
Any scratch, rash, bug bite, cut, abrasion, skin break
Contact with an infected person or any surface
Surgery / hospital; elderly, nursing homes, diabetics, gyms
www.dalosbio.com Molluscum Contagiosum
Contact with an infected person or any surface
Day care centers, gyms, other child-friendly locations
Extreme problem for pediatricians and dermatologists
www.dalosbio.com MersaDermTM – for MRSA and other skin infections
90% increase in 10 years; over 200 M reported cases
More US deaths from MRSA than from AIDS
Average cost - $60 K / patient and $5 M / hospital
Drug resistance –> Bactroban / oral antibiotics
MersaDerm meets the growing unmet need www.dalosbio.com PoxiDermTM – for Molluscum Contagiosum
200 M cases worldwide and rising rapidly
Normal treatment is to scrape, cut, burn, freeze,
Pox (smal pox) family – benign but persistent
Dermatologists and Pediatricians at a loss
No effective antiviral available until PoxiDerm www.dalosbio.com Dalos Business Description
BIO Award as “most innovative and commercializable”
Direct to Market, evidence-based products
75% increase in sales from Year 1 to Year 2
www.dalosbio.com Competition
Bactroban – drug resistance; same with oral Neosporin – no MRSA activity
No active topical products (or oral) Abhorrent in-office procedures Internet “remedies” with no basis
www.dalosbio.com Dalos Marketing Strategies
Great responses at American Academy of Dermatology and
Drive consumers to internet store – www.dalosbio.com
Traditional Distribution Channels (Chain stores)
Social Networking (Facebook, WebMD, internet sites)
www.dalosbio.com Dalos Partnering Strategies
Like-focused companies in US and world
Military (many military applications)
www.dalosbio.com Other Dalos Products
Shampoo, body wash, hand soap Now being purchased with MersaDerm and PoxiDerm
www.dalosbio.com Management Team
Dr. Gary Pekoe – President & CEO
28 years pharma / biotech product development
Scientific Advisory Committee
James Leyden, MD, U of Pennsylvania Judith Wil iams, MD, Eastern Virginia Medical School Dennis West, PhD, Northwestern University Arnold Oppenheim, MD, VA Beach Dermatology Knox Van Dyke, PhD, West Virginia U
www.dalosbio.com U.S. Projections
MersaDerm Skin infections $ 1.2 BPoxiDerm
Al other products in pipeline add to upside
Figures based on achieving investment goals
www.dalosbio.com www.dalosbio.com Conclusions
We solve the problem with MRSA, Mol uscum
Gary Pekoe, PhD 888 321-MRSA (6772) gpekoe@dalosbio.com www.dalosbio.com
Hemolytic uremic syndrome; pathogenesis, treatment,and outcomeRichard Siegler and Robert OakesThe hemolytic uremic syndrome (HUS) is the most commonAs with any syndrome, the hemolytic uremic syndromecause of acute renal failure in infants and young children,(HUS) is a constellation of features, namely the triad ofand is a substantial cause of acute mortality and chronicmicroangiopathic hemol
F E A T U R E S Mobile Power for Your Mobile Life Portable Power Outlet! No power outlet available? Socket’s got the solution! Now you can re-charge your portable electronicdevices wherever and whenever. From coffee shops totrain stations, on the plane or on the road, theSocket Mobile Power Pack is the ultimate power source Simplify your Mobile Power Needs! The S
Unique Topical 
43% of al reported skin 
Molluscum Contagiosum